Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06671008 in advanced solid tumors
NCT02659631Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Apr 2016
- Primary completion
- Mar 2019
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06671008 in solid tumor (advanced stage), triple-negative breast cancer (TNBC), colorectal cancer (CRC) and 1 more, sponsored by Pfizer. Primary endpoints: Number of Participants With Dose-Limiting Toxicities and Number of Participants With Objective Response. Started Apr 2016; status: terminated.
02
Drugs
PF-06671008
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02659631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659631.